Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?

Jan Zuna; Lenka Hovorkova; Justina Krotka; Lucie Winkowska; Zbynek Novak; Lucie Sramkova; Jan Stary; Jan Trka; Giovanni Cazzaniga; Gunnar Cario; Marketa Zaliova

doi:10.1002/ajh.27022

Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?

Am J Hematol. 2023 Oct;98(10):E269-E271. doi: 10.1002/ajh.27022. Epub 2023 Jul 14.

Authors

Jan Zuna^{1

2

3}, Lenka Hovorkova^{1

2}, Justina Krotka^{1

2

3}, Lucie Winkowska^{1

2}, Zbynek Novak⁴, Lucie Sramkova^{2

3}, Jan Stary^{2

3}, Jan Trka^{1

2

3}, Giovanni Cazzaniga⁵, Gunnar Cario⁶, Marketa Zaliova^{1

2

3}

Affiliations

¹ CLIP (Childhood Leukaemia Investigation Prague), Prague, Czech Republic.
² Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
³ University Hospital Motol, Prague, Czech Republic.
⁴ Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
⁵ Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca/Fondazione Tettamanti, Monza, Italy.
⁶ Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany.

PMID: 37449465
DOI: 10.1002/ajh.27022

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Fusion Proteins, bcr-abl / genetics
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics

Substances

Fusion Proteins, bcr-abl